Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation

Cardiovascular Research

Volumn 76, Issue 2, 2007, Pages 340-350

  Verdeguer, Francisco ^a   Castro, Claudia ^a   Kubicek, Markus ^a,b   Pla, Davinia ^a,c   Vila Caballer, Marian ^a,c   Vinué, Ángela ^a,c   Civeira, Fernando ^c,d   Pocoví, Miguel ^d   Calvete, Juan José ^a   Andrés, Vicente ^a,c  

^a INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Complement activation; ERK; Hypercholesterolemia; Macrophage; Proliferation; Vascular smooth muscle cell

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4 BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UPREGULATION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEINS E; CELL PROLIFERATION; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT SYSTEM PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; HYPERCHOLESTEROLEMIA; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE;

EID: 36649002850     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.06.028     Document Type: Article

References (52)

1. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
2. Binder C.J., Chang M.K., Shaw P.X., Miller Y.I., Hartvigsen K., Dewan A., et al. Innate and acquired immunity in atherogenesis. Nat Med 8 (2002) 1218-1226
3. Andrés V. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential. Cardiovasc Res 63 (2004) 11-21
4. Sjoholm A.G., Jonsson G., Braconier J.H., Sturfelt G., and Truedsson L. Complement deficiency and disease: an update. Mol Immunol 43 (2006) 78-85
5. Thurman J.M., and Holers V.M. The central role of the alternative complement pathway in human disease. J Immunol 176 (2006) 1305-1310
6. Oksjoki R., Kovanen P.T., Meri S., and Pentikainen M.O. Function and regulation of the complement system in cardiovascular diseases. Front Biosci 12 (2007) 4696-4708
7. Kostner K.M. Activation of the complement system: a crucial link between inflammation and atherosclerosis?. Eur J Clin Invest 34 (2004) 800-802
8. Niculescu F., and Rus H. The role of complement activation in atherosclerosis. Immunol Res 30 (2004) 73-80
9. Rus H.G., Niculescu F., and Vlaicu R. Co-localization of terminal C5b-9 complement complexes and macrophages in human atherosclerotic arterial walls. Immunol Lett 19 (1988) 27-232
10. Niculescu F., Rus H.G., and Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 65 (1987) 1-11
11. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 (2001) 1214-1219
12. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 158 (2001) 1039-1051
13. Oksjoki R., Kovanen P.T., Mayranpaa M.I., Laine P., Blom A.M., Meri S., et al. Complement regulation in human atherosclerotic coronary lesions Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway. Atherosclerosis 192 (2007) 40-48
14. Cao W., Bobryshev Y.V., Lord R.S., Oakley R.E., Lee S.H., and Lu J. Dendritic cells in the arterial wall express C1q: potential significance in atherogenesis. Cardiovasc Res 60 (2003) 175-186
15. Peerschke E.I., Minta J.O., Zhou S.Z., Bini A., Gotlieb A., Colman R.W., et al. Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions. Mol Immunol 41 (2004) 759-766
16. -/- mice via the complement system. Clin Exp Immunol 142 (2005) 441-445
17. -/- mice. Arterioscler Thromb Vasc Biol 24 (2004) 1062-1067
18. Recinos III A., Carr B.K., Bartos D.B., Boldogh I., Carmical J.R., Belalcazar L.M., et al. Liver gene expression associated with diet and lesion development in atherosclerosis-prone mice: induction of components of alternative complement pathway. Physiol Genomics 19 (2004) 131-142
19. Buono C., Come C.E., Witztum J.L., Maguire G.F., Connelly P.W., Carroll M., et al. Influence of C3 deficiency on atherosclerosis. Circulation 105 (2002) 3025-3031
20. Niculescu F., and Rus H. Complement activation and atherosclerosis. Mol Immunol 36 (1999) 949-955
21. Pang A.S., Katz A., and Minta J.O. C3 deposition in cholesterol-induced atherosclerosis in rabbits: a possible etiologic role for complement in atherogenesis. J Immunol 123 (1979) 1117-1122
22. Szeplaki G., Prohaszka Z., Duba J., Rugonfalvi-Kiss S., Karadi I., Kokai M., et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 177 (2004) 383-389
23. Speidl W.S., Exner M., Amighi J., Kastl S.P., Zorn G., Maurer G., et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 26 (2005) 2294-2299
24. Ajjan R., Grant P.J., Futers T.S., Brown J.M., Cymbalista C.M., Boothby M., et al. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 94 (2005) 1048-1053
25. Kostner K.M., Fahti R.B., Case C., Hobson P., Tate J., and Marwick T.H. Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease. Clin Chim Acta 365 (2006) 129-134
26. Meir K.S., and Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 24 (2004) 1006-1014
27. van Aalst-Cohen E.S., Jansen A.C., Tanck M.W., Defesche J.C., Trip M.D., Lansberg P.J., et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 27 (2006) 2240-2246
28. 2. Clin Chem 29 (1983) 2026-2030
29. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
30. Kip1 in smooth muscle cells from different vascular beds. A potential role in establishing regional phenotypic variance. J Biol Chem 278 (2003) 4482-4490
31. Castro C., Campistol J.M., Barettino D., and Andrés V. Transcriptional profiling of early onset diet-induced atherosclerosis in apolipoprotein E-deficient mice. Front Biosci 10 (2005) 1932-1945
32. Maslowska M., Wang H.W., and Cianflone K. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam Horm 70 (2005) 309-332
33. Stork P.J., and Schmitt J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12 (2002) 258-266
34. Schmiedt W., Kinscherf R., Deigner H.P., Kamencic H., Nauen O., Kilo J., et al. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 18 (1998) 1790-1795
35. Patel S., Thelander E.M., Hernandez M., Montenegro J., Hassing H., Burton C., et al. ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. Biochem Biophys Res Commun 286 (2001) 164-170
36. Bhatia V.K., Yun S., Leung V., Grimsditch D.C., Benson G.M., Botto M.B., et al. Complement c1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol 170 (2007) 416-426
37. Sampietro T., Bigazzi F., Rossi G., Dal Pino B., Puntoni M.R., Sbrana F., et al. Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy. J Intern Med 257 (2005) 523-530
38. Pasqui A.L., Puccetti L., Bova G., Di Renzo M., Bruni F., Pastorelli M., et al. Relationship between serum complement and different lipid disorders. Clin Exp Med 2 (2002) 33-38
39. Scantlebury T., Maslowska M., and Cianflone K. Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes. J Biol Chem 273 (1998) 20903-20909
40. Moein Moghimi S., Hamad I., Bunger R., Andresen T.L., Jorgensen K., Hunter A.C., et al. Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 16 (2006) 167-174
41. Roglic A., Prossnitz E.R., Cavanagh S.L., Pan Z., Zou A., and Ye R.D. cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim Biophys Acta 1305 (1996) 39-43
42. Monsinjon T., Gasque P., Chan P., Ischenko A., Brady J.J., and Fontaine M.C. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 17 (2003) 1003-1014
43. Monsinjon T., Gasque P., Ischenko A., and Fontaine M. C3A binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8. FEBS Lett 487 (2001) 339-346
44. 2+ influx in neutrophils via a pertussis-toxin-sensitive G protein. Eur J Biochem 217 (1993) 289-294
45. Schraufstatter I.U., Trieu K., Sikora L., Sriramarao P., and DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 169 (2002) 2102-2110
46. Bao L., Osawe I., Haas M., and Quigg R.J. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 175 (2005) 1947-1955
47. Niculescu F., Badea T., and Rus H. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis 142 (1999) 47-56
48. Fosbrink M., Niculescu F., Rus V., Shin M.L., and Rus H. C5b-9 induced endothelial cell proliferation and migration is dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281 (2006) 19009-19018
49. Lin Z.H., Fukuda N., Jin X.Q., Yao E.H., Ueno T., Endo M., et al. Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 44 (2004) 42-47
50. Chiou W.F., Tsai H.R., Yang L.M., and Tsai W.J. C5a differentially stimulates the ERK1/2 and p38 MAPK phosphorylation through independent signaling pathways to induced chemotactic migration in RAW264.7 macrophages. Int Immunopharmacol 4 (2004) 1329-1341
51. DiScipio R.G., Daffern P.J., Jagels M.A., Broide D.H., and Sriramarao P. A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 162 (1999) 1127-1136
52. Zwirner J., Werfel T., Wilken H.C., Theile E., and Gotze O. Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774. Eur J Immunol 28 (1998) 1570-1577